From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aliases SNCB, entrez:6620, synuclein beta
External IDs OMIM: 602569 MGI: 1889011 HomoloGene: 2320 GeneCards: SNCB
Gene location (Human)
Chromosome 5 (human)
Chr. Chromosome 5 (human)[1]
Chromosome 5 (human)
Genomic location for SNCB
Genomic location for SNCB
Band 5q35.2 Start 176,620,084 bp[1]
End 176,630,556 bp[1]
RNA expression pattern
PBB GE SNCB 207853 s at fs.png
More reference expression data
Species Human Mouse
RefSeq (mRNA)


RefSeq (protein)


Location (UCSC) Chr 5: 176.62 – 176.63 Mb Chr 5: 54.76 – 54.77 Mb
PubMed search [3] [4]
View/Edit Human View/Edit Mouse

Beta-synuclein is a protein that in humans is encoded by the SNCB gene.[5][6][7]

The protein encoded by this gene is highly homologous to alpha-synuclein. These proteins are abundantly expressed in the brain and putatively inhibit phospholipase D2 selectively. The encoded protein, which may play a role in neuronal plasticity, is abundant in neurofibrillary lesions of patients with Alzheimer's disease. This protein has been shown to be highly expressed in the substantia nigra of the brain, a region of neuronal degeneration in patients with Parkinson's disease; however, no direct relation to Parkinson's disease has been established. Two transcript variants encoding the same protein have been found for this gene.[7]

Beta-synuclein is a synuclein protein found primarily in brain tissue and is seen mainly in presynaptic terminals. Beta-synuclein is predominantly expressed in the neocortex, hippocampus, striatum, thalamus, and cerebellum. It is not found in Lewy bodies, but it is associated with hippocampal pathology in PD and DLB.[8]

Beta-synuclein is suggested to be an inhibitor of alpha-synuclein aggregation, which occurs in neurodegenerative diseases such as Parkinson's disease. Thus, beta-synuclein may protect the central nervous system from the neurotoxic effects of alpha-synuclein and provide a novel treatment of neurodegenerative disorders.[9][10]

See also[edit]


  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000074317 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000034891 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ Spillantini MG, Divane A, Goedert M (Nov 1995). "Assignment of human alpha-synuclein (SNCA) and beta-synuclein (SNCB) genes to chromosomes 4q21 and 5q35". Genomics. 27 (2): 379–81. doi:10.1006/geno.1995.1063. PMID 7558013. 
  6. ^ Lavedan C, Leroy E, Torres R, Dehejia A, Dutra A, Buchholtz S, Nussbaum RL, Polymeropoulos MH (Jan 1999). "Genomic organization and expression of the human beta-synuclein gene (SNCB)". Genomics. 54 (1): 173–5. doi:10.1006/geno.1998.5556. PMID 9806846. 
  7. ^ a b "Entrez Gene: SNCB synuclein, beta". 
  8. ^ George, JM (2002). "The synucleins". Genome Biology. 3 (1): REVIEWS3002. doi:10.1186/gb-2001-3-1-reviews3002. PMC 150459Freely accessible. PMID 11806835. 
  9. ^ Hashimoto, M; Bar-On, P; Ho, G; Takenouchi, T; Rockenstein, E; Crews, L; Masliah, E (2004). "Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease". The Journal of Biological Chemistry. 279 (22): 23622–9. doi:10.1074/jbc.M313784200. PMID 15026413. 
  10. ^ Hashimoto, M; Rockenstein, E; Mante, M; Mallory, M; Masliah, E (2001). "beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor". Neuron. 32 (2): 213–23. doi:10.1016/S0896-6273(01)00462-7. PMID 11683992. 

Further reading[edit]

External links[edit]